DME: lasers better than steroids

Article

Focal/grid photocoagulation is more effective than intravitreal injections of preservative-free triamcinolone for the treatment of diabetic macular oedema (DME), according to a study published in the July 2008 issue of Ophthalmology.

Focal/grid photocoagulation is more effective than intravitreal injections of preservative-free triamcinolone for the treatment of diabetic macular oedema (DME), according to a study published in the July 2008 issue of Ophthalmology. This is the first study to compare long-term laser therapy with corticosteroid treatment for DME.

Neil Bressler, MD, of the Diabetic Retinopathy Clinical Research Network and Johns Hopkins University, Baltimore, US and colleagues conducted a multicentre randomized trial of 693 DME patients (840 eyes) to assess visual acuity, retinal thickness and safety up to two years. Patients were divided into three groups to compare focal/grid photocoagulation (n=330) with 1 mg and 4 mg doses of intravitreal triamcinolone (n=256 and 254, respectively). Patients received re-treatment, if required, at four-month intervals.

In terms of mean visual acuity, 4 mg triamcinolone performed best of the three groups at four months; at one year, there was no statistically significant difference between the three groups; at 16 months and two years, laser therapy performed best, with approximately one-third of eyes in this group demonstrating "substantial improvement" in vision. Optical coherence tomography corroborated these results.

Across both corticosteroid treatment arms, 28% of eyes lost ≥2 lines, compared with 19% of laser-treated eyes. Additionally, intraocular pressure increased ≥10 mmHg from baseline in 33% of the eyes receiving treatment with 4 mg triamcinolone, in 16% of eyes receiving treatment with 1 mg triamcinolone and in 4% of eyes undergoing focal/grid photocoagulation. Cataract surgery was required in 51% of eyes receiving 4 mg triamcinolone, in 23% of eyes receiving 1 mg triamcinolone and in 13% of eyes undergoing laser therapy.

The researchers concluded that not only were the long-term visual acuity outcomes much more favourable following treatment with lasers rather than corticosteroids but also that the incidence of adverse events was lower in the laser treatment arm than in either of the corticosteroid groups.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.